[Clinical evaluation of XXXX for complicated urinary tract infection].

@entity1 @entity5646 @entity293
Efficacy and safety of @entity5646 , a monobactam antibiotic developed by E.R. Squibb _ Sons, Inc. U.S.A., in complicated @entity293 ( @entity293 ) were studied. @entity5646 was administered to 15 @entity1 with complicated @entity293 admitted to our Hospitals between July, 1984 and January, 1985. A two-gram dose of @entity5646 was administered twice a day intravenously or intraductally for 5 days consecutively. There were 11 evaluable cases in accordance with the @entity293 Drug Efficacy Evaluation Standard (the second issue). Overall clinical effect of these cases were "excellent" in 6 cases, "good" in 2 cases and "poor" in 3 cases. All the effective cases ("excellent" and "good") were of single infections and all the non-effective cases ("poor") were of complicated infections. All of the gram-negative pathogens and 4 of the 8 gram-positive pathogens were eliminated. In no cases were side effects or significantly abnormal laboratory findings reported. Therefore, @entity5646 is very effective and safe for complicated @entity293 , especially gram-negative infections.
